Goldman Sachs’s Acrivon Therapeutics ACRV Stock Holding History

Goldman Sachs’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.5K	Sell	14,742 -104,680	-88%	-$183K	﹤0.01%	6361
2025 Q4	$288K	Buy	119,422 +99,680	+505%	+$217K	﹤0.01%	5886
2025 Q3	$35.7K	Sell	19,742 -120,313	-86%	-$169K	﹤0.01%	6204
2025 Q2	$167K	Buy	140,055 +82,536	+143%	+$113K	﹤0.01%	5710
2025 Q1	$117K	Sell	57,519 -180,033	-76%	-$969K	﹤0.01%	5755
2024 Q4	$1.43M	Buy	237,552 +39,384	+20%	+$286K	﹤0.01%	4569
2024 Q3	$1.39M	Buy	198,168 +173,784	+713%	+$1.37M	﹤0.01%	4412
2024 Q2	$141K	Buy	+24,384	New	+$196K	﹤0.01%	5345
2023 Q2	–	Sell	-13,718	Closed	-$174K	–	5720
2023 Q1	$174K	Sell	13,718 -25,082	-65%	-$421K	﹤0.01%	5342
2022 Q4	$447K	Buy	+38,800	New	+$493K	﹤0.01%	4934

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's ACRV Position: Q1 2026 in Review

Goldman Sachs reduced its Acrivon Therapeutics (ACRV) stake by 88% in Q1 2026, selling an estimated $183K and leaving 14,742 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6361.

Goldman Sachs first reported a position in ACRV in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.43M in Q4 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Goldman Sachs held 14,742 shares of Acrivon Therapeutics worth $20.5K as of Q1 2026.
Goldman Sachs sold 104,680 Acrivon Therapeutics shares in Q1 2026, an estimated $183K.
Acrivon Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6361 holding.
Goldman Sachs first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 10 quarters since.
Goldman Sachs's Acrivon Therapeutics position peaked at $1.43M in Q4 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.